Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan’s RaQualia, Once Pfizer’s Nagoya Unit, Plans To Go Public

This article was originally published in PharmAsia News

Executive Summary

RaQualia Pharma, which until July 1 was the Japanese Nagoya Laboratories research unit of U.S. drug maker Pfizer, expects to go public by early 2011, thanks to a major investment by NIF SMBC Ventures. Those funds have given RaQualia enough to last for as long as five years, or past the time it is scheduled to go public. The company was formed by Nagoya personnel, and some of its drug candidates are being supplied to Pfizer. RaQualia President Atsushi Nagahisa said the 70 researchers from the former Pfizer unit pulled together to form the new company after failing to convince the U.S. firm not to close the operation. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts